Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
Status: Enrolling
Updated:  1/5/2017
Jemsek Clinic
mi
from
Huntersville, NC
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
Status: Enrolling
Updated: 1/5/2017
Jemsek Clinic
mi
from
Huntersville, NC
Click here to add this to my saved trials
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
Status: Enrolling
Updated:  1/5/2017
Tarrant County Inf Dis Assoc
mi
from
Fort Worth, TX
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
Status: Enrolling
Updated: 1/5/2017
Tarrant County Inf Dis Assoc
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
Status: Enrolling
Updated:  1/5/2017
The Schrader Clinic
mi
from
Houston, TX
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
Status: Enrolling
Updated: 1/5/2017
The Schrader Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
Status: Enrolling
Updated:  1/5/2017
Local Institution
mi
from
Rosario,
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
Status: Enrolling
Updated: 1/5/2017
Local Institution
mi
from
Rosario,
Click here to add this to my saved trials
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS
THC and Marijuana--Effects in Individuals With HIV/AIDS
Status: Enrolling
Updated:  1/10/2017
New York State Psychiatric Institute
mi
from
New York, NY
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS
THC and Marijuana--Effects in Individuals With HIV/AIDS
Status: Enrolling
Updated: 1/10/2017
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Study to Reduce Intravenous Exposures (STRIVE)
Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users
Status: Enrolling
Updated:  1/10/2017
Johns Hopkins University, Bloomberg School of Public Health
mi
from
Baltimore, MD
Study to Reduce Intravenous Exposures (STRIVE)
Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users
Status: Enrolling
Updated: 1/10/2017
Johns Hopkins University, Bloomberg School of Public Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Reduce Intravenous Exposures (STRIVE)
Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users
Status: Enrolling
Updated:  1/10/2017
New York Academy of Medicine, Center for Urban Epidemiologic Studies
mi
from
New York, NY
Study to Reduce Intravenous Exposures (STRIVE)
Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users
Status: Enrolling
Updated: 1/10/2017
New York Academy of Medicine, Center for Urban Epidemiologic Studies
mi
from
New York, NY
Click here to add this to my saved trials
Study to Reduce Intravenous Exposures (STRIVE)
Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users
Status: Enrolling
Updated:  1/10/2017
Public Health Seattle & King County
mi
from
Seattle, WA
Study to Reduce Intravenous Exposures (STRIVE)
Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users
Status: Enrolling
Updated: 1/10/2017
Public Health Seattle & King County
mi
from
Seattle, WA
Click here to add this to my saved trials
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
Status: Enrolling
Updated:  1/10/2017
University of Texas-HSC at Houston, School of Public Health
mi
from
Houston, TX
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
Status: Enrolling
Updated: 1/10/2017
University of Texas-HSC at Houston, School of Public Health
mi
from
Houston, TX
Click here to add this to my saved trials
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals
Status: Enrolling
Updated:  1/10/2017
Tufts Medical Center
mi
from
Boston, MA
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals
Status: Enrolling
Updated: 1/10/2017
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated:  1/11/2017
Adult Immunology Clinic, Highland Hospital
mi
from
Oakland, CA
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated: 1/11/2017
Adult Immunology Clinic, Highland Hospital
mi
from
Oakland, CA
Click here to add this to my saved trials
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated:  1/11/2017
AIDS Project East Bay (APEB)
mi
from
Oakland, CA
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated: 1/11/2017
AIDS Project East Bay (APEB)
mi
from
Oakland, CA
Click here to add this to my saved trials
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated:  1/11/2017
East Bay AIDS Center (EBAC), Alta Bates Hospital
mi
from
Oakland, CA
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated: 1/11/2017
East Bay AIDS Center (EBAC), Alta Bates Hospital
mi
from
Oakland, CA
Click here to add this to my saved trials
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated:  1/11/2017
Kaiser Permanente Medical Center
mi
from
San Francisco, CA
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated: 1/11/2017
Kaiser Permanente Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated:  1/11/2017
Adult Immunology Clinic, Fairmont Hospital
mi
from
San Leandro, CA
Positive Choice: Prevention for Positive Health
Positive Choice: Prevention for Positive Health
Status: Enrolling
Updated: 1/11/2017
Adult Immunology Clinic, Fairmont Hospital
mi
from
San Leandro, CA
Click here to add this to my saved trials
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated:  1/11/2017
Stanley Street Treatment and Resources
mi
from
Fall River, MA
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated: 1/11/2017
Stanley Street Treatment and Resources
mi
from
Fall River, MA
Click here to add this to my saved trials
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated:  1/11/2017
Greater New Bedford Community Center
mi
from
New Bedford, MA
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated: 1/11/2017
Greater New Bedford Community Center
mi
from
New Bedford, MA
Click here to add this to my saved trials
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated:  1/11/2017
Hope Center for HIV Care, Memorial Hospital
mi
from
Pawtucket, RI
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated: 1/11/2017
Hope Center for HIV Care, Memorial Hospital
mi
from
Pawtucket, RI
Click here to add this to my saved trials
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated:  1/11/2017
Rhode Island Hospital HIV Clinic
mi
from
Providence, RI
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated: 1/11/2017
Rhode Island Hospital HIV Clinic
mi
from
Providence, RI
Click here to add this to my saved trials
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated:  1/11/2017
The Miriam Hospital Immunology Clinic
mi
from
Providence, RI
Motivation and Patch Treatment for HIV-positive Smokers
Motivation and Patch Treatment for HIV-positive Smokers
Status: Enrolling
Updated: 1/11/2017
The Miriam Hospital Immunology Clinic
mi
from
Providence, RI
Click here to add this to my saved trials
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Status: Enrolling
Updated:  1/12/2017
University of California-Davis
mi
from
Sacramento, CA
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Status: Enrolling
Updated: 1/12/2017
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study to Evaluate the Effect of High Fat Meal on Cabotegravir
A Phase I Study Evaluating the Effect of a High Fat Meal on the Pharmacokinetics of Cabotegravir in Healthy Adult Volunteers
Status: Enrolling
Updated:  1/12/2017
GSK Investigational Site
mi
from
Overland Park, KA
A Study to Evaluate the Effect of High Fat Meal on Cabotegravir
A Phase I Study Evaluating the Effect of a High Fat Meal on the Pharmacokinetics of Cabotegravir in Healthy Adult Volunteers
Status: Enrolling
Updated: 1/12/2017
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated:  1/18/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated: 1/18/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated:  1/18/2017
The University of California, San Diego
mi
from
La Jolla, CA
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated: 1/18/2017
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated:  1/18/2017
University of California at San Diego Antiviral Research Center
mi
from
San Diego, CA
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated: 1/18/2017
University of California at San Diego Antiviral Research Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated:  1/18/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated: 1/18/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated:  1/18/2017
Beth Israel Med Ctr
mi
from
New York, NY
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated: 1/18/2017
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated:  1/18/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated: 1/18/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated:  1/18/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients
Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects
Status: Enrolling
Updated: 1/18/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Phoenix, AZ
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Bakersfield, CA
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Fountain Valley, CA
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Los Angeles, CA
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
San Francisco, CA
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Denver, CO
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Norwalk, CT
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Norwalk, CT
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Washington,
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Bradenton, FL
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Miami Beach, FL
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Miami Beach, FL
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Chicago, IL
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Indianapolis, IN
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Louisville, KY
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Baltimore, MD
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Boston, MA
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Las Vegas, NV
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Newark, NJ
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Newark, NJ
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Rochester, NY
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Greenville, SC
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated:  1/18/2017
GSK Investigational Site
mi
from
Dallas, TX
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Status: Enrolling
Updated: 1/18/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials